Amgen - Company Information
Amgen, Inc. is a biotechnology company that focuses on biopharmaceutical research, drug development, and the production of therapeutic medications, in...Read more
Headquarters
Contact
Linkedin
Company Size10,000+
Stock SymbolAMGN
Websiteamgen.com
TypePublic
Amgen Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by Amgen
Amgen Employee Profiles
Are you looking for the decision-makers at Amgen? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover Amgen’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDownload the 6sense Chrome Extension to get verified contact data of Amgen employees
Install Now
Amgen News & Press Releases
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are Amgen latest news, alerts and updates.
Jay Bradner joins Amgen as R&D head
Amgen has appointed Jay Bradner its new chief scientific officer. The former Novartis research leader succeeds David Reese, who has become Amgen's chief technology officer. The steps we are announcing today reflect our conviction that the rapid convergence of ˜biotech' and ˜tech' will unlock the next frontier of innovation in biotechnology,
5 Jan 2024
Amgen appoints James Bradner as executive VP of R&D & CSO and David M Reese named as executive VP & CTO
Amgen appoints James Bradner as executive VP of R&D & CSO and David M Reese named as executive VP & CTO: Thousand Oaks, California Saturday, December 16, 2023, 18:00 Hrs [IST] Amg
16 Dec 2023
Biogen vet's new startup raises nine-figure round, moves to Watertown
It's easily one of the largest venture capital raises of the year amid a tough market for young biotechs. Bessemer Venture Partners led the round. The venture arm of Amgen (Nasdaq: AMGN), where Viney once led inflammation research, joined in, as did Codon ...
4 Dec 2023
Tharimmune's public offering; Culmination Bio raises $10M; Pepper Bio's seed round led by NFX
Tharimmune closes $11M in public offering: The company, which is developing therapies that aim to treat rare, inflammatory, and oncologic conditions, announced Thursday that it sold 11 million shares of com ...
1 Dec 2023
Amgen's Acquisition Of Horizon Means The Stock Is A Buy
Summary Amgen completes acquisition of Horizon Therapeutics for $27.8 billion, strengthening its inflammation portfolio and expanding its international footprint. I estimate the acquisition to increase Amgen's annual revenue by 12% to 14%.
11 Oct 2023
Deal concluded: Amgen completes $27.8B acquisition of Horizon Therapeutics
Amgen announced Friday its completion of a $27.8 billion cash purchase of Horizon Therapeutics. It‚ s the largest acquisition in Amgen‚ s history. The Thousand Oaks biotech giant bought Dublin, Ireland-based Horizon Therapeutics at $116.50 per share.
8 Oct 2023
FAQs for Amgen
Explore frequently asked questions about Amgen’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
Get instant access to B2B contact data across the web
Sign Up Today
